5 FDA actions
DUPIXENT (DUPILUMAB)
REGENERON PHARMACEUTICALS
LIBTAYO (CEMIPLIMAB-RWLC)
PRALUENT (ALIROCUMAB)
INMAZEB (ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN)
EYLEA (AFLIBERCEPT)